These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
179 related articles for article (PubMed ID: 32666594)
1. In vitro stem cell modelling demonstrates a proof-of-concept for excess functional mutant TIMP3 as the cause of Sorsby fundus dystrophy. Hongisto H; Dewing JM; Christensen DR; Scott J; Cree AJ; Nättinen J; Määttä J; Jylhä A; Aapola U; Uusitalo H; Kaarniranta K; Ratnayaka JA; Skottman H; Lotery AJ J Pathol; 2020 Oct; 252(2):138-150. PubMed ID: 32666594 [TBL] [Abstract][Full Text] [Related]
2. Sorsby fundus dystrophy - A review of pathology and disease mechanisms. Christensen DRG; Brown FE; Cree AJ; Ratnayaka JA; Lotery AJ Exp Eye Res; 2017 Dec; 165():35-46. PubMed ID: 28847738 [TBL] [Abstract][Full Text] [Related]
3. Sorsby fundus dystrophy: Insights from the past and looking to the future. Anand-Apte B; Chao JR; Singh R; Stöhr H J Neurosci Res; 2019 Jan; 97(1):88-97. PubMed ID: 30129971 [TBL] [Abstract][Full Text] [Related]
4. Tissue Inhibitor of Metalloproteinase 3 (TIMP3) mutations increase glycolytic activity and dysregulate glutamine metabolism in RPE cells. Grenell A; Singh C; Raju M; Wolk A; Dalvi S; Jang GF; Crabb JS; Hershberger CE; Manian KV; Hernandez K; Crabb JW; Singh R; Du J; Anand-Apte B Mol Metab; 2024 Oct; 88():101995. PubMed ID: 39047907 [TBL] [Abstract][Full Text] [Related]
5. Molecular dissection of TIMP3 mutation S156C associated with Sorsby fundus dystrophy. Fogarasi M; Janssen A; Weber BH; Stöhr H Matrix Biol; 2008 Jun; 27(5):381-92. PubMed ID: 18295466 [TBL] [Abstract][Full Text] [Related]
6. Drusen in patient-derived hiPSC-RPE models of macular dystrophies. Galloway CA; Dalvi S; Hung SSC; MacDonald LA; Latchney LR; Wong RCB; Guymer RH; Mackey DA; Williams DS; Chung MM; Gamm DM; Pébay A; Hewitt AW; Singh R Proc Natl Acad Sci U S A; 2017 Sep; 114(39):E8214-E8223. PubMed ID: 28878022 [TBL] [Abstract][Full Text] [Related]
7. Extracellular matrix dysfunction in Sorsby patient-derived retinal pigment epithelium. Engel AL; Wang Y; Khuu TH; Worrall E; Manson MA; Lim RR; Knight K; Yanagida A; Qi JH; Ramakrishnan A; Weleber RG; Klein ML; Wilson DJ; Anand-Apte B; Hurley JB; Du J; Chao JR Exp Eye Res; 2022 Feb; 215():108899. PubMed ID: 34929159 [TBL] [Abstract][Full Text] [Related]
8. Sorsby fundus dystrophy mutation Timp3(S156C) affects the morphological and biochemical phenotype but not metalloproteinase homeostasis. Soboleva G; Geis B; Schrewe H; Weber BH J Cell Physiol; 2003 Oct; 197(1):149-56. PubMed ID: 12942551 [TBL] [Abstract][Full Text] [Related]
9. The retinal pigment epithelium in Sorsby Fundus Dystrophy shows increased sensitivity to oxidative stress-induced degeneration. Wolk A; Upadhyay M; Ali M; Suh J; Stoehr H; Bonilha VL; Anand-Apte B Redox Biol; 2020 Oct; 37():101681. PubMed ID: 32828705 [TBL] [Abstract][Full Text] [Related]
10. A mouse model for Sorsby fundus dystrophy. Weber BH; Lin B; White K; Kohler K; Soboleva G; Herterich S; Seeliger MW; Jaissle GB; Grimm C; Reme C; Wenzel A; Asan E; Schrewe H Invest Ophthalmol Vis Sci; 2002 Aug; 43(8):2732-40. PubMed ID: 12147610 [TBL] [Abstract][Full Text] [Related]
11. Deglycosylation Increases the Aggregation and Angiogenic Properties of Mutant Tissue Inhibitor of Metalloproteinase 3 Protein: Implications for Sorsby Fundus Dystrophy. Qi JH; Anand-Apte B Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430707 [TBL] [Abstract][Full Text] [Related]
12. Generation of an induced pluripotent stem cell line (SJTUGHi003-A) from a patient with Sorsby fundus dystrophy carrying c.484G>A mutation in TIMP3 gene. Zhu X; Tang L; Zhang T; Bai X; Chen J; Zhang L; Gong Y; Jiang M; Sun X Stem Cell Res; 2024 Jun; 77():103423. PubMed ID: 38640637 [TBL] [Abstract][Full Text] [Related]
13. Role of FGF and Hyaluronan in Choroidal Neovascularization in Sorsby Fundus Dystrophy. Wolk A; Hatipoglu D; Cutler A; Ali M; Bell L; Hua Qi J; Singh R; Batoki J; Karle L; Bonilha VL; Wessely O; Stoehr H; Hascall V; Anand-Apte B Cells; 2020 Mar; 9(3):. PubMed ID: 32143276 [TBL] [Abstract][Full Text] [Related]
14. The N-terminal p.(Ser38Cys) TIMP3 mutation underlying Sorsby fundus dystrophy is a founder mutation disrupting an intramolecular disulfide bond. Naessens S; De Zaeytijd J; Syx D; Vandenbroucke RE; Smeets F; Van Cauwenbergh C; Leroy BP; Peelman F; Coppieters F Hum Mutat; 2019 May; 40(5):539-551. PubMed ID: 30668888 [TBL] [Abstract][Full Text] [Related]
15. Sorsby Fundus Dystrophy Mutation in Tissue Inhibitor of Metalloproteinase 3 (TIMP3) promotes Choroidal Neovascularization via a Fibroblast Growth Factor-dependent Mechanism. Qi JH; Bell B; Singh R; Batoki J; Wolk A; Cutler A; Prayson N; Ali M; Stoehr H; Anand-Apte B Sci Rep; 2019 Nov; 9(1):17429. PubMed ID: 31757977 [TBL] [Abstract][Full Text] [Related]
16. Accumulation of tissue inhibitor of metalloproteinases-3 in human eyes with Sorsby's fundus dystrophy or retinitis pigmentosa. Fariss RN; Apte SS; Luthert PJ; Bird AC; Milam AH Br J Ophthalmol; 1998 Nov; 82(11):1329-34. PubMed ID: 9924344 [TBL] [Abstract][Full Text] [Related]
17. Review: Mechanisms of TIMP-3 accumulation and pathogenesis in Sorsby fundus dystrophy. Betts JHJ; Troeberg L Mol Vis; 2024; 30():74-91. PubMed ID: 38601018 [TBL] [Abstract][Full Text] [Related]
18. A novel His158Arg mutation in TIMP3 causes a late-onset form of Sorsby fundus dystrophy. Lin RJ; Blumenkranz MS; Binkley J; Wu K; Vollrath D Am J Ophthalmol; 2006 Nov; 142(5):839-48. PubMed ID: 16989765 [TBL] [Abstract][Full Text] [Related]